HeartBeam Cuts Costs Awaits FDA Decision

HeartBeam (NASDAQ:BEAT) reported a 23% decrease in cash burn to $3.4 million in Q2 2025, ending the period with $5.1 million in cash. The company is on track for FDA clearance of its 12-lead ECG synthesis software by Q4 2025, which will facilitate its pilot commercial launch targeting direct-pay patients in concierge practices following prior 510(k) clearance.

Want More Context? 🔎